

Arcadia Biosciences Inc

08:34 10 Dec 2019

Arcadia Biosciences launches new product line, GoodHemp

Arcadia Biosciences Inc (NASDAQ:RKDA) announced Tuesday the launch of a new product line: GoodHemp.

GoodHemp is the company's new commercial brand for delivering genetically superior hemp seeds, transplants, flower and extracts, according to a statement.

Arcadia said GoodHemp will debut its first commercial product -- a disease-resistant and ultra-low THC hemp seed -- during the American Seed Trade Association CSS & Seed Expo on December 11.

READ: Arcadia Biosciences and Bioceres Crop Solutions secure approval in Paraguay for drought-tolerant soybeans

Accepting advance orders now, the first variety in GoodHemp's catalog, Complia Bot+, is a widely-adapted cannabis strain that delivers high CBD content (more than 10%) with ultra-low tetrahydrocannabinol (THC), the psychoactive compound in cannabis.

It is part of the Complia hemp seed line Arcadia is bringing to market through GoodHemp, with four additional proprietary varieties in early adopter farmer trials with sales expected in the 2020 season.

This innovation comes just months after the US Department of Agriculture's Interim Final Ruling for hemp cultivation, which mandates that states test hemp crops and dispose of "hot" crops that exceed 0.3% THC.

While hemp farmers will have access to crop protection options, the destruction of hot crops that fail these stringent inspections will not be a covered loss under crop insurance programs. In 2019 alone, approximately 20% of US hemp crops were non-compliant, representing \$2 billion in losses for growers.

"In less than a year since we first announced our division for hemp research and cultivation, Arcadia Specialty Genomics, we've brought to market a commercial hemp line designed to solve a major industry problem - hot crops," said Sarah Reiter, chief commercial officer at Arcadia.

"This is proof of our disruptive innovation and speed to market, and it is just the beginning of our ambitions for revolutionizing the commercial hemp germplasm market."

GoodHemp the first application of ArchiTech

GoodHemp is the first application of ArchiTech, Arcadia's proprietary technology platform designed to bring innovative and disruptive plant genomics to market rapidly.

Combining modern bioscience approaches including genomics, genome editing such as CRISPR and TILLING, phenotyping and conventional breeding - along with aggressive market intelligence and partnering - Arcadia is aiming

Price: 5.1

Market Cap: \$44.1 m

1 Year Share Price Graph



February 2019 August 2019 February 2020

Share Information

Code: RKDA

Listing: NASDAQ

52 week	High	Low
	10.4	1.85

Sector: Agribusiness

Website: arcadiabio.com

Company Synopsis:

Arcadia Biosciences is a consumer-driven agricultural technology company that develops and commercializes high-value food ingredients, nutritional oils and products that help meet consumer demand for a healthier diet. Our GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace.

action@proactiveinvestors.com

modern technology at the ancient crop of hemp.

"Through our ArchiTech platform, we are combining modern breeding science and genomics technology to develop high-quality non-GM hemp varieties with improved uniformity, stability, resiliency and yield, enabling farmers to maximize the value and profitability of this newly-legal crop," added Randy Shultz, vice president of research and development at Arcadia. "In addition to this ultra-low THC disease-resistant variety, we continue to build our germplasm estate based on our own varietal developments and technology acquisitions."

A proven leader in the crop innovation discipline, Arcadia's portfolio of agricultural traits is being developed to enable farmers around the world to be more productive and minimize the impact of agriculture on the environment.

The David, California-based company focuses on three strategic crops: wheat, soybeans and hemp. The company's GoodWheat product line, which delivers nutritionally enhanced ingredients such as high fiber resistant starch and reduced gluten wheat varieties, recently made its commercial debut.

Arcadia's stock was up 5% to \$5.59 a share in pre-marketing trading,

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Arcadia Biosciences Inc named herein, including the promotion by the Company of Arcadia Biosciences Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).